Cohen SJ, et al. - A phase 1 study of imexon combined with gemcitabine demonstrated good tolerance with encouraging clinical activity. In the present randomized phase II study, it was demonstrated that imexon + gemcitabine did not provide improved outcomes, compared with gemcitabine + placebo, when administered as initial therapy in patients with metastatic pancreatic adenocarcinoma.